Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?

Stefano Cavalieri, Francesca Platini, Cristiana Bergamini, Carlo Resteghini, Donata Galbiati, Paolo Bossi, Federica Perrone, Elena Tamborini, Pasquale Quattrone, Lisa Licitra, Laura Deborah Locati, Salvatore Alfieri

Research output: Contribution to journalArticle

Abstract

Introduction: Salivary gland cancers (SGCs) are a rare and heterogeneous group of malignant tumors arising from either major or minor salivary glands. Among SGCs patients, adenoid cystic carcinoma (ACC) is the most frequent histotype and its genetic aberrations are well known even though they are generally uncommon. Non-ACC subtypes are rarer and more heterogeneous than ACC from a histological and genomic point of view. In non-ACC, some altered molecular pathways [e.g. BRAF or RET mutations, Androgen Receptor (AR)] are potentially targetable with specific drugs. Areas covered: A literature search was performed to summarize the main druggable genomic aberrations involving non-ACC SGCs. An overview of the genomics of non-ACC salivary gland malignancies is discussed. We describe the pattern of potentially targetable genomic alterations in non-ACC salivary gland malignancies according to their frequency rather than to the single non-ACC histotype. Expert opinion/commentary: The genetic profiling through in-depth molecular analyses [e.g. Next-generation sequencing (NGS)] is advised in all patients affected by recurrent and/or metastatic non-ACC SGCs to find any potentially druggable target. Some histotypes may carry driving mutations that must be investigated and defined. For the rare cancers, access to a referral center is recommended to optimize the management of these patients.

Original languageEnglish
Pages (from-to)435-443
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume28
Issue number5
DOIs
Publication statusPublished - May 4 2019

Fingerprint

Salivary Gland Neoplasms
Genomics
Carcinoma
Adenoid Cystic Carcinoma
Salivary Glands
Neoplasms
Minor Salivary Glands
Mutation
Expert Testimony
Androgen Receptors
Referral and Consultation

Keywords

  • druggable
  • genomics
  • MASCC
  • salivary duct carcinoma
  • Salivary gland cancer
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Genomics in non-adenoid cystic group of salivary gland cancers : one or more druggable entities? / Cavalieri, Stefano; Platini, Francesca; Bergamini, Cristiana; Resteghini, Carlo; Galbiati, Donata; Bossi, Paolo; Perrone, Federica; Tamborini, Elena; Quattrone, Pasquale; Licitra, Lisa; Locati, Laura Deborah; Alfieri, Salvatore.

In: Expert Opinion on Investigational Drugs, Vol. 28, No. 5, 04.05.2019, p. 435-443.

Research output: Contribution to journalArticle

@article{10867350feb24fb39278b01ce4ae7d58,
title = "Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?",
abstract = "Introduction: Salivary gland cancers (SGCs) are a rare and heterogeneous group of malignant tumors arising from either major or minor salivary glands. Among SGCs patients, adenoid cystic carcinoma (ACC) is the most frequent histotype and its genetic aberrations are well known even though they are generally uncommon. Non-ACC subtypes are rarer and more heterogeneous than ACC from a histological and genomic point of view. In non-ACC, some altered molecular pathways [e.g. BRAF or RET mutations, Androgen Receptor (AR)] are potentially targetable with specific drugs. Areas covered: A literature search was performed to summarize the main druggable genomic aberrations involving non-ACC SGCs. An overview of the genomics of non-ACC salivary gland malignancies is discussed. We describe the pattern of potentially targetable genomic alterations in non-ACC salivary gland malignancies according to their frequency rather than to the single non-ACC histotype. Expert opinion/commentary: The genetic profiling through in-depth molecular analyses [e.g. Next-generation sequencing (NGS)] is advised in all patients affected by recurrent and/or metastatic non-ACC SGCs to find any potentially druggable target. Some histotypes may carry driving mutations that must be investigated and defined. For the rare cancers, access to a referral center is recommended to optimize the management of these patients.",
keywords = "druggable, genomics, MASCC, salivary duct carcinoma, Salivary gland cancer, targeted therapy",
author = "Stefano Cavalieri and Francesca Platini and Cristiana Bergamini and Carlo Resteghini and Donata Galbiati and Paolo Bossi and Federica Perrone and Elena Tamborini and Pasquale Quattrone and Lisa Licitra and Locati, {Laura Deborah} and Salvatore Alfieri",
year = "2019",
month = "5",
day = "4",
doi = "10.1080/13543784.2019.1598376",
language = "English",
volume = "28",
pages = "435--443",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Genomics in non-adenoid cystic group of salivary gland cancers

T2 - one or more druggable entities?

AU - Cavalieri, Stefano

AU - Platini, Francesca

AU - Bergamini, Cristiana

AU - Resteghini, Carlo

AU - Galbiati, Donata

AU - Bossi, Paolo

AU - Perrone, Federica

AU - Tamborini, Elena

AU - Quattrone, Pasquale

AU - Licitra, Lisa

AU - Locati, Laura Deborah

AU - Alfieri, Salvatore

PY - 2019/5/4

Y1 - 2019/5/4

N2 - Introduction: Salivary gland cancers (SGCs) are a rare and heterogeneous group of malignant tumors arising from either major or minor salivary glands. Among SGCs patients, adenoid cystic carcinoma (ACC) is the most frequent histotype and its genetic aberrations are well known even though they are generally uncommon. Non-ACC subtypes are rarer and more heterogeneous than ACC from a histological and genomic point of view. In non-ACC, some altered molecular pathways [e.g. BRAF or RET mutations, Androgen Receptor (AR)] are potentially targetable with specific drugs. Areas covered: A literature search was performed to summarize the main druggable genomic aberrations involving non-ACC SGCs. An overview of the genomics of non-ACC salivary gland malignancies is discussed. We describe the pattern of potentially targetable genomic alterations in non-ACC salivary gland malignancies according to their frequency rather than to the single non-ACC histotype. Expert opinion/commentary: The genetic profiling through in-depth molecular analyses [e.g. Next-generation sequencing (NGS)] is advised in all patients affected by recurrent and/or metastatic non-ACC SGCs to find any potentially druggable target. Some histotypes may carry driving mutations that must be investigated and defined. For the rare cancers, access to a referral center is recommended to optimize the management of these patients.

AB - Introduction: Salivary gland cancers (SGCs) are a rare and heterogeneous group of malignant tumors arising from either major or minor salivary glands. Among SGCs patients, adenoid cystic carcinoma (ACC) is the most frequent histotype and its genetic aberrations are well known even though they are generally uncommon. Non-ACC subtypes are rarer and more heterogeneous than ACC from a histological and genomic point of view. In non-ACC, some altered molecular pathways [e.g. BRAF or RET mutations, Androgen Receptor (AR)] are potentially targetable with specific drugs. Areas covered: A literature search was performed to summarize the main druggable genomic aberrations involving non-ACC SGCs. An overview of the genomics of non-ACC salivary gland malignancies is discussed. We describe the pattern of potentially targetable genomic alterations in non-ACC salivary gland malignancies according to their frequency rather than to the single non-ACC histotype. Expert opinion/commentary: The genetic profiling through in-depth molecular analyses [e.g. Next-generation sequencing (NGS)] is advised in all patients affected by recurrent and/or metastatic non-ACC SGCs to find any potentially druggable target. Some histotypes may carry driving mutations that must be investigated and defined. For the rare cancers, access to a referral center is recommended to optimize the management of these patients.

KW - druggable

KW - genomics

KW - MASCC

KW - salivary duct carcinoma

KW - Salivary gland cancer

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85065323249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065323249&partnerID=8YFLogxK

U2 - 10.1080/13543784.2019.1598376

DO - 10.1080/13543784.2019.1598376

M3 - Article

C2 - 30897975

AN - SCOPUS:85065323249

VL - 28

SP - 435

EP - 443

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 5

ER -